Your browser doesn't support javascript.
Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
El-Shesheny, Rabeh; El Taweel, Ahmed; Gomaa, Mokhtar R; Roshdy, Wael H; Kandeil, Ahmed; Webby, Richard J; Kayali, Ghazi; Ali, Mohamed A.
  • El-Shesheny R; Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt. Electronic address: rabeh.elshesheny@human-link.org.
  • El Taweel A; Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt. Electronic address: Ahmed.Nageh@human-link.org.
  • Gomaa MR; Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt. Electronic address: Mokhtar.Rizk@human-link.org.
  • Roshdy WH; Central Public Health Laboratory, Ministry of Health and Population, Cairo, Egypt. Electronic address: waelhamedroshdy@yahoo.com.
  • Kandeil A; Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38107, USA. Electronic address: Ahmed.Kandeil@human-link.org.
  • Webby RJ; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38107, USA. Electronic address: Richard.webby@stjude.org.
  • Kayali G; Human Link, Dubai, UAE. Electronic address: ghazi@human-link.org.
  • Ali MA; Centre of Scientific Excellence for Influenza Viruses, Environmental Research Division, National Research Centre, Giza 12622, Egypt. Electronic address: Mohamed.Ali@human-link.org.
Vaccine ; 40(32): 4303-4306, 2022 07 30.
Article in English | MEDLINE | ID: covidwho-1882607
ABSTRACT
The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa Language: English Journal: Vaccine Year: 2022 Document Type: Article